Expedient synthesis of highly potent antagonists of inhibitor of apoptosis proteins (IAPs) with unique selectivity for ML-IAP.

No abstract is available for this paper.

• Publication year

  2013

• Venue

  ACS Chemical Biology

• Publication date

  2013-02-05

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1021/cb3005512PMID 23323685PMCID PMC3953502
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Characterization of ML-IAP protein stability and physiological role in vivo.

  2012cited by this paper
• Discovery of a potent small-molecule antagonist of inhibitor of apoptosis (IAP) proteins and clinical candidate for the treatment of cancer (GDC-0152).

  2012cited by this paper
• TRAIL Signaling and Synergy Mechanisms Used in TRAIL-Based Combination Therapies

  2012cited by this paper
• A Small Molecule SMAC Mimic LBW242 Potentiates TRAIL- and Anticancer Drug-Mediated Cell Death of Ovarian Cancer Cells

  2012cited by this paper
• Targeting IAP proteins for therapeutic intervention in cancer

  2012cited by this paper
• The hallmarks of cancer

  2012cited by this paper
• Design, synthesis and evaluation of monovalent Smac mimetics that bind to the BIR2 domain of the anti-apoptotic protein XIAP.

  2011cited by this paper
• A potent and orally active antagonist (SM-406/AT-406) of multiple inhibitor of apoptosis proteins (IAPs) in clinical development for cancer treatment.

  2011cited by this paper
• Design of small-molecule Smac mimetics as IAP antagonists.

  2010cited by this paper
• Antagonists of inhibitor of apoptosis proteins based on thiazole amide isosteres.

  2010cited by this paper
• Recognition of Smac‐mimetic compounds by the BIR domain of cIAP1

  2010cited by this paper
• Orally bioavailable antagonists of inhibitor of apoptosis proteins based on an azabicyclooctane scaffold.

  2009cited by this paper
• The inhibitor of apoptosis protein Livin (ML-IAP) plays a dual role in tumorigenicity.

  2009cited by this paper
• Human Caspases: Activation, Specificity, and Regulation*

  2009cited by this paper
• The mechanism of peptide-binding specificity of IAP BIR domains

  2008cited by this paper
• Challenge and promise: roles for Livin in progression and therapy of cancer

  2008cited by this paper
• Autocrine TNFalpha signaling renders human cancer cells susceptible to Smac-mimetic-induced apoptosis.

  2007cited by this paper
• Highly efficient synthesis of azabicyclo[x.y.0]alkane amino acids and congeners by means of Rh-catalyzed cyclohydrocarbonylation.

  2007cited by this paper
• Design, synthesis, and biological activity of a potent Smac mimetic that sensitizes cancer cells to apoptosis by antagonizing IAPs.

  2006cited by this paper
• Building functionalized peptidomimetics: use of electroauxiliaries for introducing N-acyliminium ions into peptides.

  2006cited by this paper
• gem-disubstituent effect: theoretical basis and synthetic applications.

  2005cited by this paper
• XIAP inhibits caspase‐3 and ‐7 using two binding sites: evolutionarily conserved mechanism of IAPs

  2005cited by this paper
• Rhodium-catalyzed intramolecular hydroacylation of 5- and 6-alkynals: convenient synthesis of alpha-alkylidenecycloalkanones and cycloalkenones.

  2004cited by this paper
• Discovery of potent antagonists of the antiapoptotic protein XIAP for the treatment of cancer.

  2004cited by this paper
• Peptide Syntheses via Ugi Reactions with Ammonia.

  2004cited by this paper
• Development and optimization of a binding assay for the XIAP BIR3 domain using fluorescence polarization.

  2004cited by this paper
• Peptide Syntheses via Ugi Reactionswith Ammonia

  2003cited by this paper
• Mechanisms of cancer drug resistance.

  2002cited by this paper
• Livin, a Novel Inhibitor of Apoptosis Protein Family Member*

  2001cited by this paper
• A convenient and versatile synthesis of 6,5- and 7,5-fused bicyclic lactams as peptidomimetics

  2001cited by this paper
• Multicomponent Reactions with Isocyanides.

  2000cited by this paper
• Structural basis for binding of Smac/DIABLO to the XIAP BIR3 domain

  2000cited by this paper
• ML-IAP, a novel inhibitor of apoptosis that is preferentially expressed in human melanomas.

  2000cited by this paper
• KIAP, a novel member of the inhibitor of apoptosis protein family.

  2000cited by this paper
• 2-(2-AMINOPHENYL)-ACETALDEHYDE DIMETHYL ACETAL : A NOVEL REAGENT FOR THE PROTECTION OF CARBOXYLIC ACIDS

  1998cited by this paper
• 2‐(2‐Aminophenyl)‐acetaldehyde Dimethyl Acetal: A Novel Reagent for the Protection of Carboxylic Acids.

  1998cited by this paper
• Dual metalloprotease inhibitors: mercaptoacetyl-based fused heterocyclic dipeptide mimetics as inhibitors of angiotensin-converting enzyme and neutral endopeptidase.

  1997cited by this paper
• Synthesis and analysis of Leu-enkephalin analogues containing reverse turn peptidomimetics

  1996cited by this paper
• Electrochemical Cyclization of Dipeptides To Form Novel Bicyclic, Reverse-Turn Peptidomimetics. 2. Synthesis and Conformational Analysis of 6,5-Bicyclic Systems

  1996cited by this paper
• Electrochemical Cyclization of Dipeptides toward Novel Bicyclic, Reverse-Turn Peptidomimetics. 1. Synthesis and Conformational Analysis of 7,5-Bicyclic Systems

  1995cited by this paper
• Synthesis of potential β-turn bicyclic dipeptide mimetics

  1993cited by this paper

• Chiral Phosphoric Acid-Catalyzed Kinetic Resolution of Tertiary Alcohol-Tethered Ynamides via Controllable Hydroalkoxylation

  2025cites this paper
• Copper catalyzed Shono-type oxidation of proline residues in peptide

  2023cites this paper
• So Pathogenic or So What?—A Brief Overview of SIV Pathogenesis with an Emphasis on Cure Research

  2022cites this paper
• Strategies to Reduce the On‐Target Platelet Toxicity of Bcl‐xL Inhibitors: PROTACs, SNIPERs and Prodrug‐Based Approaches

  2022cites this paper
• Discovery of E3 Ligase Ligands for Target Protein Degradation

  2022cites this paper
• Cell Survival and Cell Death at the Intersection of Autophagy and Apoptosis: Implications for Current and Future Cancer Therapeutics.

  2021cites this paper
• Lysine Covalent Antagonists of Melanoma Inhibitors of Apoptosis Protein.

  2021cites this paper
• Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies

  2020influential citation
• Pd-Catalyzed asymmetric [5 + 2] cycloaddition of vinylethylene carbonates and cyclic imines: access to N-fused 1,3-oxazepines.

  2020cites this paper
• Discovery of IAP-recruiting BCL-XL PROTACs as potent degraders across multiple cancer cell lines.

  2020influential citation
• Pharmacological Activation of Non-canonical NF-κB Signaling Activates Latent HIV-1 Reservoirs In Vivo

  2020cites this paper
• Development of XIAP Antagonists Based On De Novo 8,5‐Fused Bicyclic Lactams†

  2019cites this paper
• Targeting the BIR Domains of Inhibitor of Apoptosis (IAP) Proteins in Cancer Treatment

  2019cites this paper
• Negative regulators of cell death pathways in cancer: perspective on biomarkers and targeted therapies

  2018cites this paper
• Aminolactam, N-Aminoimidazolone, and N-Aminoimdazolidinone Peptide Mimics

  2017cites this paper
• Assessment of spatially inhomogeneous intra-organ radiation dose response in salivary glands

  2017cites this paper
• Inducing death in tumor cells: roles of the inhibitor of apoptosis proteins

  2017cites this paper
• Synthesis, Reactions and Uses of Isocyanides in Organic Synthesis. An Update

  2016cites this paper
• Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis

  2016cites this paper
• BIRC2/cIAP1 Suppresses HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency

  2015cites this paper
• BIRC2/cIAP1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency.

  2015cites this paper
• Multicomponent Reactions with a Convertible Isocyanide: Efficient and Versatile Grafting of ADMET-Derived Polymers

  2014cites this paper
• Antagonists of IAP proteins: novel anti-tumor agents.

  2014cites this paper
• 2-Aminopyridines via reaction of pyridine N-oxides and activated isocyanides.

  2014cites this paper
• Triggering necroptosis in cisplatin and IAP antagonist-resistant ovarian carcinoma

  2014cites this paper
• Caspase enzymology and activation mechanisms.

  2014cites this paper
• Small molecule modulators of protein-protein interactions: selected case studies.

  2014cites this paper
• Design, synthesis and evaluation of inhibitor of apoptosis protein (IAP) antagonists that are highly selective for the BIR2 domain of XIAP.

  2013cites this paper
• Small-Molecule IAP Antagonists Sensitize Cancer Cells to TRAIL-Induced Apoptosis: Roles of XIAP and cIAPs

  2013cites this paper
• Inhibitor of apoptosis proteins (IAPs) as regulatory factors of hepatic apoptosis.

  2013cites this paper
• BIRC 2 / cIAP 1 Is a Negative Regulator of HIV-1 Transcription and Can Be Targeted by Smac Mimetics to Promote Reversal of Viral Latency Graphical

  year unknowncites this paper